Langedijk, Annefleur C.
Vrancken, Bram http://orcid.org/0000-0001-6547-5283
Lebbink, Robert Jan http://orcid.org/0000-0002-1981-0420
Wilkins, Deidre
Kelly, Elizabeth J. http://orcid.org/0000-0002-6988-8576
Baraldi, Eugenio
Mascareñas de Los Santos, Abiel Homero
Danilenko, Daria M. http://orcid.org/0000-0001-6174-0836
Choi, Eun Hwa
Palomino, María Angélica
Chi, Hsin http://orcid.org/0000-0002-2385-344X
Keller, Christian http://orcid.org/0000-0002-0075-7199
Cohen, Robert
Papenburg, Jesse
Pernica, Jeffrey
Greenough, Anne http://orcid.org/0000-0002-8672-5349
Richmond, Peter
Martinón-Torres, Federico http://orcid.org/0000-0002-9023-581X
Heikkinen, Terho
Stein, Renato T.
Hosoya, Mitsuaki
Nunes, Marta C. http://orcid.org/0000-0003-3788-878X
Verwey, Charl
Evers, Anouk
Kragten-Tabatabaie, Leyla
Suchard, Marc A. http://orcid.org/0000-0001-9818-479X
Kosakovsky Pond, Sergei L.
Poletto, Chiara http://orcid.org/0000-0002-4051-1716
Colizza, Vittoria http://orcid.org/0000-0002-2113-2374
Lemey, Philippe http://orcid.org/0000-0003-2826-5353
Bont, Louis J. http://orcid.org/0000-0003-3099-4475
Priante, Elena
Komissarova, Kseniya
Yun, Ki Wook
Clement, Pascale
Bauck, Monica
Gupta, Atul
Wadia, Ushma
Rivero-Calle, Irene
Lumertz, Magalia
Hasimoto, Koichi
Madhi, Shabir A.
,
Funding for this research was provided by:
AstraZeneca
Article History
Received: 12 April 2023
Accepted: 14 March 2024
First Online: 10 April 2024
Competing interests
: L.J.B. has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. U.M.C.U. has received major funding (>€100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. U.M.C.U. has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. U.M.C.U. has received major funding from Julius Clinical for participating in the INFORM-RSV study sponsored by AstraZeneca and Sanofi. U.M.C.U. has received minor funding for participation in trials by Regeneron and Janssen from 2015–2017 (total annual estimate less than €20,000). U.M.C.U. received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, and Janssen (total annual estimate less than €20,000). L.J.B. is the founding chairman of the ReSViNET Foundation. P.L. and M.A.S. acknowledge support from the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 725422-ReservoirDOCS), from the Wellcome Trust through project 206298/Z/17/Z and from the NIH grant R01 AI153044. P.L. acknowledges support from the Research Foundation - Flanders (‘Fonds voor Wetenschappelijk Onderzoek - Vlaanderen’, G0D5117N and G051322N) and from the European Union’s Horizon 2020 project MOOD (grant agreement no. 874850). D.W. and E.J.K. are employees of AstraZeneca. The remaining authors declare no competing interests.